
Merck and Samsung Bioepis have formed an agreement to develop and commercialize multiple prespecified and undisclosed biosimilar candidates.

Merck and Samsung Bioepis have formed an agreement to develop and commercialize multiple prespecified and undisclosed biosimilar candidates.

FDA has released a list of more than 50 guidance documents planned for 2013.

FDA has released a list of more than 50 guidance documents planned for 2013.

NIBRT's Michael Lacey provides an overview of biopharmaceutical facility design and operation.

A look at vaccine history, markets, manufacturing, and overcoming the scale-up dilemma.

Improvement strategy should be linked to business strategy.

Rutgers engineers constructed a direct compaction line in collaboration with Janssen.

Therapeutics targeting epigenetic mechanisms of disease will change the pharmaceutical marketplace.

What the industry's future holds and what needs to be done to get there.

NIBRT's Ray O'Connor provides an overview of aseptic processing.

Recent research examines the sequence of events underlying cellular reprogramming, which may aid in better control of the production of induced pluripotent stem cells.

This month, Sharon Strause, an industry consultant, provides a look back at "Computer System Validation Part I: Testing and Verification of Applications Software" by Leonard J. Goren.

The European Commission (EC) is seeking to introduce a black symbol to identify medicines that are subject to additional monitoring.

An operation spanning 16 African countries and conducted by the World Customs Organization (WCO) in partnership with the Institute of Research against Counterfeit Medicines (IRACM) led to the seizure of more than 82 million doses of counterfeit medicines.

This case study describes the process used to transition from a multi-use system to single-use tangential flow filtration for performing final buffer exchange steps.

Industry experts from GE Healthcare, Tarpon Biosystems, Polybatics, Merck Millipore, and Repligen discuss the challenges of adapting disposable technology to the chromatography process.

This article describes best practices for implementing a single-use process train at a bioproduction facility.

The combination of single-use platform technology with modular facility construction is a template for flexible manufacturing.

A brief case study of a facility-fit analysis provides insight into how to adjust capacity when moving from clinical-to commercial-scale production.

The authors explain why Catalent decided to transition from stainless steel to single-use systems.

GE Healthcare Life Sciences' ReadyToProcess platform aims to streamline bioprocessing.

Insights on single-use systems implementation and exploitation in biopharmaceutical manufacturing and processing, based on a QbD approach.

Is process-centered organization in biopharmaceutical manufacturing a stepping stone or a stumbling block?

Scaling up stem-cell cultures requires careful consideration of the bioreactor design.

Creating an effective nucleic acid-based vaccine requires protecting the fragile nucleic acid from degradation, effective transfection of the targeted cells, and producing high enough levels of antigen to evoke a robust immune response.